Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc. sold a total of 128,385 shares of Eli Lilly & Co. common stock on May 29, 2024, at various weighted average prices.

Summary

• Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., executed multiple sales of common stock on May 29, 2024.
• The transactions involved the disposal of 128,385 shares in total.
• The sales were conducted at weighted average prices ranging from $809.345 to $815.35 per share.
• Following these transactions, Lilly Endowment Inc. still holds a substantial 98,423,810 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a stock sale. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are a routine part of regulatory compliance for significant shareholders and insiders, providing transparency into their trading activities. This filing indicates a reduction in Lilly Endowment Inc.'s holdings in Eli Lilly & Co.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting insider transactions in publicly traded companies, such as Eli Lilly & Co.
• The reported transactions are similar to those of other major shareholders in large pharmaceutical companies, such as Pfizer or Johnson & Johnson, who are also required to disclose their trading activities.
• The weighted average prices reported are consistent with the typical reporting of multiple transactions within a single day.

Stakeholder Impact

• The sale of shares by a major shareholder like Lilly Endowment Inc. could potentially have a minor impact on the share price of Eli Lilly & Co.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, stock sale, share disposal, insider trading, Form 4, shareholder